What do systematic reviews say?

Xiao Chai Hu Tang formula vs no intervention

The review found no eligible studies for this question.

• Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupuncture vs no intervention

The review found no eligible studies for this question.

• Acupuncture for chronic hepatitis B 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

T‐cell antibody induction vs placebo or no intervention

T‐cell antibody induction may leads to lower mortality Mortality at latest compared with placebo/no intervention (low certainty).

• Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients 2014 · Cochrane Headline outcomes only
  RR 0.91
  16 studies · 1853 participants
  Low

Fibrin‐based haemostatic agents vs placebo or no intervention

It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with no intervention or placebo (very low certainty).

• Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection 2023 · Cochrane Headline outcomes only
  RR 2.58 [0.89, 7.44]
  4 studies · 782 participants
  Very low

Antibiotics vs placebo or no intervention

Antibiotics showed no clear difference in all‐cause mortality at maximum compared with placebo or no intervention (high certainty).

• Antibiotics for secondary prevention of coronary heart disease 2021 · Cochrane Headline outcomes only
  RR 1.06 [0.99, 1.13]
  20 studies · 25774 participants
  High

Beta‐blockers vs placebo or no intervention

Beta‐blockers probably leads to lower all‐cause mortality at maximum compared with placebo or no intervention (moderate certainty).

• Beta‐blockers for suspected or diagnosed acute myocardial infarction 2019 · Cochrane Headline outcomes only
  RR 0.93 [0.86, 0.99]
  21 studies · 25210 participants
  Moderate

Berotralstat vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avoralstat vs placebo

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Lanadelumab vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antibiotics vs placebo or no intervention

Antibiotics leads to higher all‐cause mortality at 24±6 months compared with placebo or no intervention (high certainty).

• Antibiotics for secondary prevention of coronary heart disease 2021 · Cochrane Headline outcomes only
  RR 1.25 [1.06, 1.48]
  6 studies · 9517 participants
  High

Antibiotics vs placebo or no intervention

Antibiotics leads to higher cardiovascular mortality at 24±6 months compared with placebo or no intervention (high certainty).

• Antibiotics for secondary prevention of coronary heart disease 2021 · Cochrane Headline outcomes only
  RR 1.5 [1.17, 1.91]
  5 studies · 9044 participants
  High
• Antibiotics for secondary prevention of coronary heart disease 2021 · Cochrane Headline outcomes only
  RR 1.11 [0.98, 1.25]
  2 studies · 4674 participants
  Moderate

Beta‐blockers vs placebo or no intervention

Beta‐blockers probably leads to lower cardiovascular mortality at maximum compared with placebo or no intervention (moderate certainty).

• Beta‐blockers for suspected or diagnosed acute myocardial infarction 2019 · Cochrane Headline outcomes only
  RR 0.9 [0.83, 0.98]
  14 studies · 22457 participants
  Moderate
• Beta‐blockers for suspected or diagnosed acute myocardial infarction 2019 · Cochrane Headline outcomes only
  RR 0.99 [0.91, 1.08]
  1 study · 45852 participants
  Moderate

Sildenafil vs IV nitroglycerin

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Low

Sildenafil vs Placebo or no active treatment

Sildenafil citrate showed no clear difference in neonatal mortality compared with placebo or no therapy (moderate certainty).

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  RR 1.45 [0.9, 2.33]
  5 studies · 397 participants
  Moderate

Tadalafil vs Placebo or no active treatment

Tadalafil showed no clear difference in neonatal mortality compared with placebo or no therapy (low certainty).

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.06, 13.7]
  1 study · 83 participants
  Low

Nitroglycerin vs Placebo or no active treatment

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Low